Proposed Collection; Comment Request; The National Diabetes Education Program Survey of the Public, 42348-42349 [05-14491]
Download as PDF
<![CDATA[
42348
Federal Register / Vol. 70, No. 140 / Friday, July 22, 2005 / Notices
Dated: July 6, 2005.
Elizabeth M. Duke,
Administrator.
Bureau of Primary Health Care (BPHC)
(RC)
Provides overall leadership, direction,
coordination, and strategic planning in
support of Bureau programs.
Specifically:(1) Has lead responsibility
to bring primary health care services to
the Nation’s neediest communities; (2)
serves as a central point of contact for
Bureau communication and
information; (3) establishes program
policies, goals, and objectives and
provides oversight as to their execution;
(4) interprets program policies,
guidelines, and priorities; (5) stimulates,
coordinates and evaluates program
development and progress; (6)
maintains effective relationships with
HRSA, other Department and Health
and Human Services (HHS)
organizations, other Federal agencies,
State and local governments, and other
public and private organizations
concerned with primary health and
improving the health status of the
Nation’s underserved and vulnerable
populations; (7) plans, directs,
coordinates and evaluates Bureau-wide
administrative management activities;
and (8) assures BPHC’s funding
recommendations are consistent with
authorizing legislation, program
expectations and HHS and HRSA
policies.
Dated: July 6, 2005.
Elizabeth M. Duke,
Administrator.
Bureau of Primary Health Care (BPHC)
(RC)Division of Policy and
Development (RCH)
The Division of Policy and
Development serves as the
organizational focus of the competitive
grant process for BPHC; and leads in
drafting policy and conducting analyses
of performance across BPHC’s programs.
Specifically, the DPD executes the
following activities: (1) Leads and
monitors the development and
expansion of health centers and health
systems infrastructure; (2) provides preapplication assistance to communities
and community-based organizations
related to the development and
expansion of health centers and health
systems infrastructure; (3) consults and
coordinates with other components
within HRSA, other Federal agencies,
consumer and constituency groups, and
national and State organizations on
issues affecting BPHC’s programs; (4)
formulates budget justifications for
BPHC’s programs and provides input
VerDate jul<14>2003
19:28 Jul 21, 2005
Jkt 205001
into the analysis of BPHC budget
execution; (5) leads and coordinates the
analysis, development and drafting of
policy impacting BPHC’s programs; (6)
performs environmental scanning on
issues that affect BPHC’s programs; (7)
serves as the focal point for designing
and implementing a plan for assessing
and improving program performance;
and (8) serves as the focal point for
monitoring BPHC’s activities in relation
to HRSA’s Strategic Plan.
Dated: July 6, 2005.
Elizabeth M. Duke,
Administrator.
[FR Doc. 05–14485 Filed 7–21–05; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Proposed Collection; Comment
Request; The National Diabetes
Education Program Survey of the
Public
SUMMARY: Under provisions of Section
3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, the National
Institute of Diabetes and Digestive and
Kidney Diseases (NIDDK), the National
Institutes of Health (NIH) has submitted
to the Office of Management and Budget
(OMB) a request for review and
approval of the information collection
listed below. This proposed information
collection was previously published in
the Federal Register on September 9,
2003, pages 53176–53177, and allowed
60 days for public comment. No public
comments were received. The purpose
of this notice is to allow an additional
30 days for public comment. The
National Institutes of Health may not
conduct or sponsor, and the respondent
is not required to respond to, an
information collection that has been
extended, revised, or implemented on or
after October 1, 1995, unless it displays
a currently valid OMB control number.
Proposed Collection: Title: The
National Diabetes Educations Program
Survey of the Public. Type of
Information Collection Request: New.
Need and Use of Information Collection:
The National Diabetes Education
Program (NDEP) is a partnership of the
National Institutes of Health (NIH) and
the Centers for Disease Control and
Prevention (CDC) and more than 200
public and private organizations. The
long-term goals of the NDEP are to
improve the treatment and health
outcomes of people with diabetes, to
promote early diagnosis, and,
ultimately, to prevent the onset of
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
diabetes. The NDEP objectives are: (1)
To increase awareness of the
seriousness of diabetes, its risk factors,
and strategies for preventing diabetes
and its complications among people at
risk for diabetes; (2) to improve
understanding about diabetes and its
control and to promote better selfmanagement behaviors among people
with diabetes; (3) to improve health care
providers’ understanding of diabetes
and its control and to promote an
integrated approach to care; (4) to
promote health care policies that
improve the quality of and access to
diabetes care.
Multiple strategies have been devised
to address the NDEP objectives. These
have been described in the NDEP
Strategic Plan and include: (1) Creating
partnerships with other organizations
concerned about diabetes; (2)
developing and implementing
awareness and education activities with
special emphasis on reaching the racial
and ethnic populations
disproportionately affected by diabetes;
(3) identifying, developing, and
disseminating educational tools and
resources for the program’s diverse
audiences; (4) promoting policies and
activities to improve the quality of and
access to diabetes care.
The NDEP evaluation will document
the extent to which the NDEP program
has been implemented, and how
successful it has been in meeting
program objectives. The evaluation
relies heavily on data gathered from
existing national surveys such as
National Health and Nutrition
Examination Survey (NHANES), the
National Health Interview Survey
(NHIS), the Behavioral Risk Factor
Surveillance System (BRFSS), among
others for this information. This
clearance request is for the collection of
additional primary data from NDEP
target audiences on some key process
and impact measures that are necessary
to effectively evaluate the program.
Approval is requested for survey of the
public including people at risk for
diabetes, people with diabetes and their
families.
Frequency of Response: On occasion.
Affected Public: Individuals or
households. Type of Respondents:
Adults. The annual reporting burden is
as follows: Estimated Number of
Respondents: 1600; Estimated Number
of Responses per Respondent: 1;
Average Burden Hours per Response:
.25; and Estimated Total Annual Burden
Hours Requested: 400. The annualized
cost to respondents is estimated at:
$8,000.00. There are no Capital Costs to
report. There are no Operating or
Maintenance Costs to report.
E:\FR\FM\22JYN1.SGM
22JYN1
42349
Federal Register / Vol. 70, No. 140 / Friday, July 22, 2005 / Notices
ESTIMATES OF HOUR BURDEN
Number of respondents
Type of respondents
Frequency of
response
Average time
per response
Total hour burden
Public, including people at risk for diabetes, patients and their family members ..............................................................................................................
1600
1
.25
400
Totals ........................................................................................................
1,600
........................
........................
400
Frequency of
response
Hourly wage
rate
COST TO RESPONDENTS
Number of respondents
Type of respondents
Respondent
cost
Public, including people at risk for diabetes, patients and their family members ..............................................................................................................
1600
1
$20.00
$8,000.00
Total ..........................................................................................................
........................
........................
........................
$8,000.00
Request for Comments: Written
comments and/or suggestions from the
public and affected agencies are invited
on one or more of the following points:
(1) Whether the proposed collection of
information is necessary for the proper
performance of the function of the
agency, including whether the
information will have practical utility;
(2) The accuracy of the agency’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) Ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
Ways to minimize the burden of the
collection of information on those who
are to respond, including the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms of
information technology.
Direct Comments to OMB: Written
comments and/or suggestions regarding
the item(s) contained in this notice,
especially regarding the estimated
public burden and associated response
time, should be directed to the Office of
Management and Budget, Office of
Regulatory Affairs, New Executive
Office Building, Room 10235,
Washington, DC 20503, Attention: Desk
Officer for NIH. To request more
information on the proposed project or
to obtain a copy of the data collection
plans and instruments, contact Joanne
Gallivan, M.S., R.D., Director, National
Diabetes Education Program, NIDDK,
NIH, Building 31, Room 9A04, 31
Center Drive, Bethesda, MD 20892, or
call non-toll-free number (301) 494–
6110 or e-mail your request, including
your address to:
Joanne_Gallivan@nih.gov.
Comments Due Date: Comments
regarding this information collection are
best assured of having their full effect
VerDate jul<14>2003
19:28 Jul 21, 2005
Jkt 205001
received within 30 days of the date of
this publication.
Dated: June 28, 2005.
Barbara Merchant,
Executive Officer, NIDDK, National Institutes
of Health.
[FR Doc. 05–14491 Filed 7–21–05; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing and
Cooperative Research and
Development Agreement (CRADA):
Aminoflavone Prodrug
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: The inventions described
below are owned by an agency of the
U.S. Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 in association with
collaborative research via a Cooperative
Research and Development Agreement
(CRADA) with the National Cancer
Institute (NCI) of the National Institutes
of Health. This opportunity is being
offered to achieve expeditious
commercialization of results of federally
funded research and development.
Foreign patent applications are filed on
selected inventions to extend market
coverage for companies and may also be
available for licensing.
ADDRESSES: Licensing information may
be obtained by contacting George G.
Pipia, PhD., at the Office of Technology
Transfer, National Institutes of Health,
6011 Executive Boulevard, Suite 325,
Rockville, MD 20852–3804; telephone:
PO 00000
Frm 00051
Fmt 4703
Sfmt 4703
301/435–5560; fax: 301/402–0220; email: PipiaG@mail.nih.gov.
CRADA inquiries may be addressed to
Robert Wagner, M.S., M. Phil., at the
Technology Transfer Branch, National
Cancer Institute, 6120 Executive
Boulevard, Suite 450, Rockville, MD
20852; telephone: 301/496–0477; fax:
301–402–2117; e-mail:
WagnerB@mail.nih.gov.
Information regarding NCI drug
development collaborations with the
Cancer Therapy Evaluation Program can
be found at https://ctep.cancer.gov/.
SUPPLEMENTARY INFORMATION: Scientists
at the National Cancer Institute (NCI),
NIH, have developed a novel anti-cancer
agent, the aminoflavone prodrug (AFP–
464, NSC 710464) which is a lysyl
prodrug of aminoflavone (AF, NSC
686288). AFP–464 displays improved
solubility in aqueous solutions over the
parent compound AF and can be
converted rapidly to AF in plasma. In
the NCI 60-cell-line screen, both AFP–
464 and AF have demonstrated antiproliferative activity against several
renal, breast and ovarian cancer cell
lines. AFP–464 and AF have also
demonstrated anti-tumor activity in
human renal and breast carcinoma
xenografts. Pharmacokinetic studies and
toxicology studies of AFP–464 have
been completed.
The results of the pre-clinical studies
conducted by NCI have led to a decision
by the NCI to initiate NCI-sponsored
clinical trials of AFP–464. The Cancer
Therapy Evaluation Program (CTEP),
NCI expects to file an Investigational
New Drug Application with the FDA for
AFP–464 before the end of 2005.
Patent Portfolio: The patent portfolio
for the aminoflavone compounds and
the aminoflavone prodrug, claiming the
compositions of matter and methods in
the treatment of cancer includes issued
patents and patent applications
E:\FR\FM\22JYN1.SGM
22JYN1
]]>Agencies
[Federal Register Volume 70, Number 140 (Friday, July 22, 2005)]
[Notices]
[Pages 42348-42349]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-14491]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Proposed Collection; Comment Request; The National Diabetes
Education Program Survey of the Public
SUMMARY: Under provisions of Section 3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, the National Institute of Diabetes and Digestive
and Kidney Diseases (NIDDK), the National Institutes of Health (NIH)
has submitted to the Office of Management and Budget (OMB) a request
for review and approval of the information collection listed below.
This proposed information collection was previously published in the
Federal Register on September 9, 2003, pages 53176-53177, and allowed
60 days for public comment. No public comments were received. The
purpose of this notice is to allow an additional 30 days for public
comment. The National Institutes of Health may not conduct or sponsor,
and the respondent is not required to respond to, an information
collection that has been extended, revised, or implemented on or after
October 1, 1995, unless it displays a currently valid OMB control
number.
Proposed Collection: Title: The National Diabetes Educations
Program Survey of the Public. Type of Information Collection Request:
New. Need and Use of Information Collection: The National Diabetes
Education Program (NDEP) is a partnership of the National Institutes of
Health (NIH) and the Centers for Disease Control and Prevention (CDC)
and more than 200 public and private organizations. The long-term goals
of the NDEP are to improve the treatment and health outcomes of people
with diabetes, to promote early diagnosis, and, ultimately, to prevent
the onset of diabetes. The NDEP objectives are: (1) To increase
awareness of the seriousness of diabetes, its risk factors, and
strategies for preventing diabetes and its complications among people
at risk for diabetes; (2) to improve understanding about diabetes and
its control and to promote better self-management behaviors among
people with diabetes; (3) to improve health care providers'
understanding of diabetes and its control and to promote an integrated
approach to care; (4) to promote health care policies that improve the
quality of and access to diabetes care.
Multiple strategies have been devised to address the NDEP
objectives. These have been described in the NDEP Strategic Plan and
include: (1) Creating partnerships with other organizations concerned
about diabetes; (2) developing and implementing awareness and education
activities with special emphasis on reaching the racial and ethnic
populations disproportionately affected by diabetes; (3) identifying,
developing, and disseminating educational tools and resources for the
program's diverse audiences; (4) promoting policies and activities to
improve the quality of and access to diabetes care.
The NDEP evaluation will document the extent to which the NDEP
program has been implemented, and how successful it has been in meeting
program objectives. The evaluation relies heavily on data gathered from
existing national surveys such as National Health and Nutrition
Examination Survey (NHANES), the National Health Interview Survey
(NHIS), the Behavioral Risk Factor Surveillance System (BRFSS), among
others for this information. This clearance request is for the
collection of additional primary data from NDEP target audiences on
some key process and impact measures that are necessary to effectively
evaluate the program. Approval is requested for survey of the public
including people at risk for diabetes, people with diabetes and their
families.
Frequency of Response: On occasion. Affected Public: Individuals or
households. Type of Respondents: Adults. The annual reporting burden is
as follows: Estimated Number of Respondents: 1600; Estimated Number of
Responses per Respondent: 1; Average Burden Hours per Response: .25;
and Estimated Total Annual Burden Hours Requested: 400. The annualized
cost to respondents is estimated at: $8,000.00. There are no Capital
Costs to report. There are no Operating or Maintenance Costs to report.
[[Page 42349]]
Estimates of Hour Burden
----------------------------------------------------------------------------------------------------------------
Number of Frequency of Average time Total hour
Type of respondents respondents response per response burden
----------------------------------------------------------------------------------------------------------------
Public, including people at risk for diabetes, 1600 1 .25 400
patients and their family members..............
-----------------
Totals...................................... 1,600 .............. .............. 400
----------------------------------------------------------------------------------------------------------------
Cost to Respondents
----------------------------------------------------------------------------------------------------------------
Number of Frequency of Hourly wage Respondent
Type of respondents respondents response rate cost
----------------------------------------------------------------------------------------------------------------
Public, including people at risk for diabetes, 1600 1 $20.00 $8,000.00
patients and their family members..............
-----------------
Total....................................... .............. .............. .............. $8,000.00
----------------------------------------------------------------------------------------------------------------
Request for Comments: Written comments and/or suggestions from the
public and affected agencies are invited on one or more of the
following points: (1) Whether the proposed collection of information is
necessary for the proper performance of the function of the agency,
including whether the information will have practical utility; (2) The
accuracy of the agency's estimate of the burden of the proposed
collection of information, including the validity of the methodology
and assumptions used; (3) Ways to enhance the quality, utility, and
clarity of the information to be collected; and (4) Ways to minimize
the burden of the collection of information on those who are to
respond, including the use of appropriate automated, electronic,
mechanical, or other technological collection techniques or other forms
of information technology.
Direct Comments to OMB: Written comments and/or suggestions
regarding the item(s) contained in this notice, especially regarding
the estimated public burden and associated response time, should be
directed to the Office of Management and Budget, Office of Regulatory
Affairs, New Executive Office Building, Room 10235, Washington, DC
20503, Attention: Desk Officer for NIH. To request more information on
the proposed project or to obtain a copy of the data collection plans
and instruments, contact Joanne Gallivan, M.S., R.D., Director,
National Diabetes Education Program, NIDDK, NIH, Building 31, Room
9A04, 31 Center Drive, Bethesda, MD 20892, or call non-toll-free number
(301) 494-6110 or e-mail your request, including your address to:
Joanne--Gallivan@nih.gov.
Comments Due Date: Comments regarding this information collection
are best assured of having their full effect received within 30 days of
the date of this publication.
Dated: June 28, 2005.
Barbara Merchant,
Executive Officer, NIDDK, National Institutes of Health.
[FR Doc. 05-14491 Filed 7-21-05; 8:45 am]
BILLING CODE 4140-01-M
